<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366052</url>
  </required_header>
  <id_info>
    <org_study_id>NUCES_NASH-JGU</org_study_id>
    <secondary_id>SCHA 1015/5-1</secondary_id>
    <nct_id>NCT02366052</nct_id>
  </id_info>
  <brief_title>Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study</brief_title>
  <acronym>NucesNASH</acronym>
  <official_title>Nutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to determine if an oral supplementation of the LCS has a
      beneficial effect by itself or even enhances the beneficial effects of a moderate life-style
      intervention on the progression of NAFLD in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Actual">May 10, 2017</completion_date>
  <primary_completion_date type="Actual">May 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of the M30 antigen in the serum</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Reduction of the M30 antigen as a validated measure of the degree of hepatocellular inflammation and injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in indicators of hepatocellular injury and fibrosis</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Change in indicators of hepatocellular injury (ALT, gammaGT, M30/M60 antigen ratio, ELF score), proinflammatory cytokines (hsCRP, ferritin, plasminogen activator-1, endotoxin), surrogate parameters of liver fibrosis (fibrosis marker panels, Fibrotest, ELF score) and relative liver stiffness (assessed by Fibro Scan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic risk factors</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes in metabolic risk factors (BMI, waist circumference, Homeostasis Model Assessment/Matsuda Score, serum lipids), changes in oral glucose tolerance and changes in hepatic steatosis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saftey and tolerability</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Safety is assessed by (1) clinical examination, (2) clinical chemistries including serum electrolytes, renal, liver function tests and markers of pancreatic injury.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in measures of nutritional physiology</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Improvement of nutritional physiology, compliance, self-perceived efficacy, emotional eating behavior using a validated questionnaires.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>Nutritional Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional Counseling and LCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus Casei Shirota</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional Counseling</intervention_name>
    <description>Nutritional counseling by a trained nutritionist for 12 weeks.</description>
    <arm_group_label>Nutritional Counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus casei shirota (LCS)</intervention_name>
    <description>The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.</description>
    <arm_group_label>Lactobacillus Casei Shirota</arm_group_label>
    <other_name>Yakult plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutritional Counseling and LCS</intervention_name>
    <description>Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.</description>
    <arm_group_label>Nutritional Counseling and LCS</arm_group_label>
    <other_name>Nutritional Counseling and Yakult plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Elevated M30 antigen levels (cutoff: &gt;200 - 800 U/L) at screening AND hepatic steatosis
        on ultrasound

        OR histologically confirmed NASH

        - Age 18 to 75 years

        Exclusion Criteria:

          -  Alcohol intake of more than 30 g/d (men) or 20 g/d (women)

          -  Treatment with ursodeoxycholic acid (UDCA), Vitamin E or other investigational NASH
             drugs 3 months prior to randomization

          -  Treatment with medications or substances that may induce secondary NASH (e.g.,
             tamoxifen, corticosteroids, amiodarone, methotrexate) or ameliorate NASH
             (TNF-antagonists)

          -  Treatment with phenprocoumon or warfarin

          -  Hepatocellular carcinoma or non-hepatic malignancy

          -  Decompensated cirrhosis (Child B,C) or a history of decompensation

          -  Liver disease unrelated to NASH, including chronic viral hepatitis B/D or C,
             autoimmune hepatitis, Wilson's disease or clinical manifest iron overload

          -  Bariatric surgery within the last 5 years

          -  BMI &lt;18,5 kg/m2 or BMI &gt;45 kg/m2

          -  Liver transplantation

          -  Heart failure (New York Heart Association Class II - IV)

          -  Myocardial infarction, instable coronary artery disease , coronary artery intervention
             or stroke in the previous 6 months

          -  Instable chronic obstructive pulmonary disease, chronic inflammatory bowel disease or
             rheumatoid arthritis.

          -  Instable renal insufficiency (changes in serum creatinin &gt; 50% in the last 3 month) or
             terminal renal insufficiency requiring dialysis

          -  Uncontrolled hypertension (blood pressure &gt; 180/90 despite therapy)

          -  Uncontrolled diabetes mellitus defined by hemoglobin A1c &gt; 9

          -  Food allergies requiring strictly dietary adherence

          -  Pregnant or nursing women

          -  Chronic pancreatitis or history of recurring acute pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörn M Schattenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg Universität</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ina Bergheim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut für Ernährungswissenschaften, University Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenber Univeristy</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Priv.-Doz. Dr. J. Schattenberg</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Histologically confirmed NASH</keyword>
  <keyword>Hepatocyte Injury determined by M30 antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

